Back to Search Start Over

Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs.

Authors :
Darragh LB
Nguyen A
Pham TT
Idlett-Ali S
Knitz MW
Gadwa J
Bukkapatnam S
Corbo S
Olimpo NA
Nguyen D
Van Court B
Neupert B
Yu J
Ross RB
Corbisiero M
Abdelazeem KNM
Maroney SP
Galindo DC
Mukdad L
Saviola A
Joshi M
White R
Alhiyari Y
Samedi V
Van Bokhoven A
St John M
Karam SD
Source :
Med (New York, N.Y.) [Med] 2024 Mar 08; Vol. 5 (3), pp. 254-270.e8. Date of Electronic Publication: 2024 Feb 28.
Publication Year :
2024

Abstract

Background: Perineural invasion (PNI) and nerve density within the tumor microenvironment (TME) have long been associated with worse outcomes in head and neck squamous cell carcinoma (HNSCC). This prompted an investigation into how nerves within the tumor microenvironment affect the adaptive immune system and tumor growth.<br />Methods: We used RNA sequencing analysis of human tumor tissue from a recent HNSCC clinical trial, proteomics of human nerves from HNSCC patients, and syngeneic orthotopic murine models of HPV-unrelated HNSCC to investigate how sensory nerves modulate the adaptive immune system.<br />Findings: Calcitonin gene-related peptide (CGRP) directly inhibited CD8 T cell activity in vitro, and blocking sensory nerve function surgically, pharmacologically, or genetically increased CD8 and CD4 T cell activity in vivo.<br />Conclusions: Our data support sensory nerves playing a role in accelerating tumor growth by directly acting on the adaptive immune system to decrease Th1 CD4 T cells and activated CD8 T cells in the TME. These data support further investigation into the role of sensory nerves in the TME of HNSCC and points toward the possible treatment efficacy of blocking sensory nerve function or specifically inhibiting CGRP release or activity within the TME to improve outcomes.<br />Funding: 1R01DE028282-01, 1R01DE028529-01, 1P50CA261605-01 (to S.D.K.), 1R01CA284651-01 (to S.D.K.), and F31 DE029997 (to L.B.D.).<br />Competing Interests: Declaration of interests S.D.K. receives clinical funding from Genentech that does not relate to this work. She receives clinical trial funding from AstraZeneca, a part of which is included in this manuscript. She also receives preclinical research funding from Roche and Amgen unrelated to this manuscript. R.W. serves in an advisory role for AstraZeneca.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2666-6340
Volume :
5
Issue :
3
Database :
MEDLINE
Journal :
Med (New York, N.Y.)
Publication Type :
Academic Journal
Accession number :
38423011
Full Text :
https://doi.org/10.1016/j.medj.2024.02.002